The VISICOIL marker: What you see is what you treat!
The clinical success of focused, dose-delivery procedures such as intensity modulated radiation therapy (IMRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. VISICOIL TM markers allow for accurate tumor localization, using a variety of visualization techniques, and help these focal radiotherapy procedures provide the following:
- Higher doses to the tumor and periphery
- Accurate daily patient positioning
- Dose escalation in a given session
- Real-time targeting of tumors and tumor beds
- Image-fusion between various visualization modes (CT, MRI, Ultrasound)
- On-line treatment planning procedures/protocols
VISICOIL TM is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future theraputic procedures, per the US FDA approved 510(K).
Currently, the device has been developed for use in marking the prostate and periprostatic tissue. Other potential organs that may benefit from VISICOIL TM include:Liver, Breast, Cervix, Lungs, Tongue, Esophagus
By design, the VISICOIL TM markers are made to facilitate:
- Patient positioning in focused field radiation therapies such as intensity modulated radiation therapy (IMRT), conformal radiation therapy (CRT) and proton therapy, etc.
- Defining the boundary of the prostate in brachytherapy, HDR
- Image fusion between MRI and CT or CT and ultrasound
|
